Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
There are no records.

Web Desc
Engineering the Genome joint with Emerging Cellular Therapies: Cancer and Beyond Organizer(s): Vic Myer and Erik Sontheimer Date: February 08 - 12, 2020 Location: Fairmont Banff Springs, Banff, AB, Canada Sponsored by Editas Medicine and Novo Nordisk A/S For important information on the coronavirus, please click here Summary of Meeting: Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement. Scholarship Deadline: October 29 2019 Discounted Abstract Deadline: October 29 2019 Abstract Deadline: November 6 2019 Discounted Registration Deadline: December 10 2019 Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested. Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support from these exhibitors at this conference: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Illumina Intellia Therapeutics Sangamo Therapeutics, Inc. Keystone Symposia thanks the following Donors for their support of $2,500 - $4,999. We gratefully acknowledge the generous grant for this conference provided by: National Center for Advancing Translational Sciences (NCATS) Grant No. 1R13TR003025-01 Funding for this conference was made possible (in part) by 1R13TR003025-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. This award reflects support from the NIH Common Fund Somatic Cell Genome Editing (SCGE) program in the amount of $22,200 total costs. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Engineering the Genome

joint with Emerging Cellular Therapies: Cancer and Beyond

Organizer(s): Vic Myer and Erik Sontheimer

Date: February 08 - 12, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada

Sponsored by Editas Medicine and Novo Nordisk A/S

For important information on the coronavirus, please click here

Summary of Meeting:

Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement.

Scholarship Deadline: October 29 2019

Discounted Abstract Deadline: October 29 2019

Abstract Deadline: November 6 2019

Discounted Registration Deadline: December 10 2019

Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support from these exhibitors at this conference:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Illumina

Intellia Therapeutics

Sangamo Therapeutics, Inc.

Keystone Symposia thanks the following Donors for their support of $2,500 - $4,999.

We gratefully acknowledge the generous grant for this conference provided by:

National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR003025-01
Funding for this conference was made possible (in part) by 1R13TR003025-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. This award reflects support from the NIH Common Fund Somatic Cell Genome Editing (SCGE) program in the amount of $22,200 total costs.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Saturday, February 08 \| 4:00PM - 8:00PM Arrival and Registration Room: Van Horne Foyer
Saturday, February 08 \| 6:00PM - 8:00PM Welcome Mixer Room: Van Horne Foyer No registration fees are used to fund alcohol served at this function.
Sunday, February 09 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Sunday, February 09 \| 8:00AM - 9:30AM Welcome and Keynote Session (Joint) Room: Van Horne A/B Speaker 1 of 5 * Vic E. Myer, Atlas Ventures, USA
Sunday, February 09 \| 8:00AM - 9:30AM Welcome and Keynote Session (Joint) Room: Van Horne A/B Speaker 2 of 5 * Crystal L. Mackall, Stanford University, USA
Sunday, February 09 \| 8:00AM - 9:30AM Welcome and Keynote Session (Joint) Room: Van Horne A/B Speaker 3 of 5 Jennifer A. Doudna, HHMI/University of California, Berkeley, USA Genome Editing with CRISPR-Cas Systems: Challenges and Opportunities in a New Era of Biology
Sunday, February 09 \| 8:00AM - 9:30AM Welcome and Keynote Session (Joint) Room: Van Horne A/B Speaker 4 of 5 Carl H. June, University of Pennsylvania, USA Updates with Engineered T Cells
Sunday, February 09 \| 8:00AM - 9:30AM Welcome and Keynote Session (Joint) Room: Van Horne A/B Coffee Break
Sunday, February 09 \| 9:50AM - 12:00PM Biochemistry, Biophysics and New Enzymes Room: Van Horne C Speaker 1 of 5 Kira S. Makarova, National Center for Biotechnology Information, USA In silico Discovery of New Defense Systems
Sunday, February 09 \| 9:50AM - 12:00PM Biochemistry, Biophysics and New Enzymes Room: Van Horne C Speaker 2 of 5 * Erik Sontheimer, University of Massachusetts Medical School, USA RNA-Guided RNA/DNA Cleavage by CRISPR-Cas Systems
Sunday, February 09 \| 9:50AM - 12:00PM Biochemistry, Biophysics and New Enzymes Room: Van Horne C Speaker 3 of 5 Ilya J. Finkelstein, University of Texas at Austin, USA Massively-Parallel Profiling of Natural and Engineered High-Fidelity CRISPR Nucleases
Sunday, February 09 \| 9:50AM - 12:00PM Biochemistry, Biophysics and New Enzymes Room: Van Horne C Speaker 4 of 5 Ervin Welker, Research Center of Natural Sciences, Hungary Short Talk: Ranking between Increased Fidelity SpCas9 Nucleases and Target Sites
Sunday, February 09 \| 9:50AM - 12:00PM Biochemistry, Biophysics and New Enzymes Room: Van Horne C Speaker 5 of 5 Garrett R. Rettig, Integrated DNA Technologies, USA Short Talk: Engineered A.s. and L.b. Cas12a (Cpf1) Variants with Enhanced Activity
Sunday, February 09 \| 9:50AM - 12:00PM Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 6 * Chiara Bonini, Ospedale San Raffaele, Italy
Sunday, February 09 \| 9:50AM - 12:00PM Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 6 Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA CAR T Cells for Solid Tumors
Sunday, February 09 \| 9:50AM - 12:00PM Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 6 Yvonne Y. Chen, University of California, Los Angeles, USA Synthetic Biology to Engineer More Potent CAR T Cells
Sunday, February 09 \| 9:50AM - 12:00PM Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 4 of 6 Kristen Hege, Celgene, USA Clinical Development of BCMA Targeted Immunotherapies in Multiple Myeloma
Sunday, February 09 \| 9:50AM - 12:00PM Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 6 Brooke Prinzing, St. Jude Children's Research Hospital, USA Short Talk: Chimeric Antigen Receptors with a MyD88 and CD40 Costimulatory Endodomain Endow T Cells with Superior Antitumor Activity
Sunday, February 09 \| 9:50AM - 12:00PM Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 6 of 6 Evan William Weber, Stanford University, USA Short Talk: The Src Kinase Inhibitor, Dasatinib, Enhances CAR-T Cell Potency by Mitigating T Cell Exhaustion
Sunday, February 09 \| 12:00PM - 5:00PM On Own for Lunch
Sunday, February 09 \| 12:00PM - 1:00PM Poster Setup Room: Mezzanine 2
Sunday, February 09 \| 1:00PM - 10:00PM Poster Viewing Room: Mezzanine 2
Sunday, February 09 \| 2:30PM - 4:30PM Panel: Ethics of Genome Editing Room: Van Horne C Speaker 1 of 5 * Tim Hunt, Editas Medicine, USA Ethics of Genome Editing: Framing the Discussion
Sunday, February 09 \| 2:30PM - 4:30PM Panel: Ethics of Genome Editing Room: Van Horne C Speaker 2 of 5 Fyodor D. Urnov, University of California, Berkeley, USA
Sunday, February 09 \| 2:30PM - 4:30PM Panel: Ethics of Genome Editing Room: Van Horne C Speaker 3 of 5 Kathy K. Niakan, Francis Crick Institute, UK
Sunday, February 09 \| 2:30PM - 4:30PM Panel: Ethics of Genome Editing Room: Van Horne C Speaker 4 of 5 Francoise Baylis, Dalhousie University, Canada
Sunday, February 09 \| 2:30PM - 4:30PM Panel: Ethics of Genome Editing Room: Van Horne C Speaker 5 of 5 Krishanu Saha, University of Wisconsin-Madison, USA
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 8 * Manfred Lehner, Children's Cancer Research Institute, Austria
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 8 Carla Alicia Jaeger-Ruckstuhl, Fred Hutchinson Cancer Research Center, USA The Role of CD27 Co-Stimulation during CAR-T Cell Generation and Immunotherapy
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 8 Benjamin Salzer, Children's Cancer Research Institute, Austria AvidCARs – A Novel Platform for Inducible and Combinatorial CAR Control
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 4 of 8 Alec Wilkens, Fred Hutchinson Cancer Research Center, USA NOTCH1 Agonism Alters Phenotype and Function of Gene Engineered CD4+ T Cells
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 8 Michela Consonni, Fondazione Centro San Raffaele, Italy Donor-Unrestricted Adoptive T Cell Therapy of Acute Leukemia by CD1c-Restricted TCR Transfer
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 6 of 8 Amy N. Courtney, Baylor College of Medicine, USA NKT Cells Suppress Metastatic Spread of Neuroblastoma by Controlling Tumor-Associated Macrophages
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 7 of 8 Hyun Cheol Jung, Korea Advanced Institute of Science and Technology, South Korea Elimination of Amyloid-beta Plaques by Chimeric Phagocytic Receptors
Sunday, February 09 \| 2:30PM - 4:30PM Workshop 1: Platforms for Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 8 of 8 Charlotte U. Brey, Children's Cancer Research Institute, Austria A Conformation-Specific ON-Switch for Controlling CAR T Cells with an Orally Available Drug
Sunday, February 09 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Sunday, February 09 \| 5:00PM - 7:00PM In vivo Genome Editing Room: Van Horne C Speaker 1 of 6 * Fyodor D. Urnov, University of California, Berkeley, USA
Sunday, February 09 \| 5:00PM - 7:00PM In vivo Genome Editing Room: Van Horne C Speaker 2 of 6 James M. Wilson, University of Pennsylvania, USA In vivo Editing to Primate Liver
Sunday, February 09 \| 5:00PM - 7:00PM In vivo Genome Editing Room: Van Horne C Speaker 3 of 6 Edward J. Rebar, Sangamo Therapeutics, Inc., USA Liver Editing in vivo for Therapeutic Gene Expression
Sunday, February 09 \| 5:00PM - 7:00PM In vivo Genome Editing Room: Van Horne C Speaker 4 of 6 Jessica Seitzer, Intellia Therapeutics Inc., USA Short Talk: In vivo Delivery of CRISPR/Cas9 to the Liver using Lipid Nanoparticles Enables Gene Knockout across Multiple Targets in Rodent and Non-Human Primates
Sunday, February 09 \| 5:00PM - 7:00PM In vivo Genome Editing Room: Van Horne C Speaker 5 of 6 David V. Schaffer, University of California, Berkeley, USA Engineering and Evolving New Viruses for Gene Therapy and Genome Editing
Sunday, February 09 \| 5:00PM - 7:00PM In vivo Genome Editing Room: Van Horne C Speaker 6 of 6 Jessie R. Davis, Harvard University, USA Short Talk: Cytosine and Adenine Base Editing of Brain, Retina, Heart, Muscle, and Liver Mediated by AAV
Sunday, February 09 \| 5:00PM - 7:00PM Engineered Hematopoietic Stem Cells for Treatment of Genetic Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 5 * Gloria Delfanti, Fondazione Centro San Raffaele, Italy
Sunday, February 09 \| 5:00PM - 7:00PM Engineered Hematopoietic Stem Cells for Treatment of Genetic Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 5 Marina Cavazzana, Paris Descartes University, France Gene Therapy for Immunodeficiencies
Sunday, February 09 \| 5:00PM - 7:00PM Engineered Hematopoietic Stem Cells for Treatment of Genetic Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 5 Alessandra Biffi, Dana-Farber Cancer Institute, Boston Children's Hospital, USA Engineered HSCs for Correction of CNS Disorders
Sunday, February 09 \| 5:00PM - 7:00PM Engineered Hematopoietic Stem Cells for Treatment of Genetic Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 4 of 5 Sebastian Ricardo Palacios, Massachusetts Institute of Technology, USA Short Talk: Engineered RNAi-based Logic Circuits in Human Induced Pluripotent Stem Cells and their Differentiated Derivatives
Sunday, February 09 \| 5:00PM - 7:00PM Engineered Hematopoietic Stem Cells for Treatment of Genetic Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 5 Esmond Lee, Stanford, USA Short Talk: CRISPR- Based Gene Editing Enables FOXP3 Gene Repair in IPEX Patient Cells and HSPCs
Sunday, February 09 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Sunday, February 09 \| 7:30PM - 10:00PM Poster Session 1 Room: Mezzanine 2
Monday, February 10 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 1 of 9 * David R. Liu, Broad Institute, HHMI, and Harvard University, USA
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 2 of 9 Kathy K. Niakan, Francis Crick Institute, UK Towards an Understanding of Human Development Using Gene Ablation
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 3 of 9 Hannah N. De Jong, Stanford University, USA Short Talk: Deep Mutational Scanning to Identify Cardiac Disease Gene Variants
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 4 of 9 Philipp Junker, Max Delbrück Center for Molecular Medicine, Germany Massively Parallel Lineage Tracing Using CRISPR/Cas9
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Coffee Break
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 6 of 9 Alan Huang, Tango Therapeutics, USA Novel Therapeutic Opportunities Identified by Synthetic Lethal Screening
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 7 of 9 Andrew Ravanelli, MilliporeSigma, USA Short Talk: Direct Capture of CRISPR Guides Enables Scalable, Multiplexed, and Multi-Omic Genetic Screens
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 8 of 9 Birgit C. Schultes, IntelliaTherapeutics Inc., USA Developing Next-Generation Engineered TCR-T Cells with CRISPR
Monday, February 10 \| 8:00AM - 11:15AM Genome Editing as a Biology Discovery Tool Room: Van Horne C Speaker 9 of 9 Barbara Mair, University of Toronto, Canada Short Talk: High-Throughput Genome-Wide Phenotypic Screening via Immunomagnetic Cell Sorting Identifies QPCTL as Modulator of CD47
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 9 * Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 9 Crystal L. Mackall, Stanford University, USA Engineering Enhanced Potency T Cells
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 9 Chiara Bonini, Ospedale San Raffaele, Italy Multiple Genome Editing of Early Differentiated T Cells for Cancer Immunotherapy
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Coffee Break
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 9 Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, USA Targeting Solid Malignancies with 'Public' Neoantigen TCRs
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 6 of 9 Aude G. Chapuis, Fred Hutchinson Cancer Research Center, USA Optimizing T Cell Receptor Gene Therapy Against Solid and Liquid Tumors
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 7 of 9 Christie Ciarlo, Altius Institute for Biomedical Sciences, USA Short Talk: Engineering Superior T Cell Therapies without Genetic Modification
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 8 of 9 Giedre Krenciute, St Jude Children's Research Hospital, USA Short Talk: DNMT3a-Mediated Epigenetic Programming Limits CAR T Cell Survival and Effector Function
Monday, February 10 \| 8:00AM - 11:15AM Next Generation Immune Cell Engineering This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 9 of 9 Debattama Sen, Harvard Medical School, USA Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control
Monday, February 10 \| 11:15AM - 5:00PM On Own for Lunch
Monday, February 10 \| 11:15AM - 1:00PM Poster Setup Room: Mezzanine 2
Monday, February 10 \| 1:00PM - 10:00PM Poster Viewing Room: Mezzanine 2
Monday, February 10 \| 3:00PM - 4:30PM Workshop: Bacterial Adaptive Immunity Anti-CRISPR Room: Van Horne C Speaker 1 of 6 * Yan Zhang, University of Michigan, USA
Monday, February 10 \| 3:00PM - 4:30PM Workshop: Bacterial Adaptive Immunity Anti-CRISPR Room: Van Horne C Speaker 2 of 6 Joseph Bondy-Denomy, University of California, San Francisco, USA Inhibition of CRISPR-Cas9 and Cas12 with Bacteriophage Proteins
Monday, February 10 \| 3:00PM - 4:30PM Workshop: Bacterial Adaptive Immunity Anti-CRISPR Room: Van Horne C Speaker 3 of 6 Jan Mathony, Heidelberg University, Germany Computational Design of Anti-CRISPR Proteins with Improved Inhibition Potency
Monday, February 10 \| 3:00PM - 4:30PM Workshop: Bacterial Adaptive Immunity Anti-CRISPR Room: Van Horne C Speaker 4 of 6 Jooyoung Lee, University of Massachusetts Medical School, USA Tissue-Restricted Genome Editing in vivo Specified by MicroRNA-Repressible Anti-CRISPR Proteins
Monday, February 10 \| 3:00PM - 4:30PM Workshop: Bacterial Adaptive Immunity Anti-CRISPR Room: Van Horne C Speaker 5 of 6 Dominik Niopek, Heidelberg University Hospital, Germany Switchable Anti-CRISPR Proteins for Precision Control of CRISPR-Cas9 and -12
Monday, February 10 \| 3:00PM - 4:30PM Workshop: Bacterial Adaptive Immunity Anti-CRISPR Room: Van Horne C Speaker 6 of 6 Jennifer R. Hamilton, University of California, Berkeley, USA Delivery of Anti-CRISPR Proteins by Engineered Virus-Like Particles Therapeutically Protect Cells from CRISPR-Cas9 Gene Editing
Monday, February 10 \| 3:30PM - 4:30PM Workshop 2: HSC and iPSC Engineering and Therapy This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 5 * Katy Rezvani, University of Texas MD Anderson Cancer Center, USA
Monday, February 10 \| 3:30PM - 4:30PM Workshop 2: HSC and iPSC Engineering and Therapy This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 5 Linda T. Vo, University of California, San Francisco, USA A Stem Cell Platform for Engineering Distinct T Cell Populations de novo for Immunotherapy
Monday, February 10 \| 3:30PM - 4:30PM Workshop 2: HSC and iPSC Engineering and Therapy This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 5 Brian Koss, University of Arkansas for Medical Sciences, USA Epigenetic Control of Tumor-Infiltrating Lymphocyte Metabolic-Exhaustion
Monday, February 10 \| 3:30PM - 4:30PM Workshop 2: HSC and iPSC Engineering and Therapy This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 4 of 5 Bernhard Lehnertz, University of Montreal, Canada Engineering of a Genetically Encoded Human Hematopoietic Stem Cell Reporter
Monday, February 10 \| 3:30PM - 4:30PM Workshop 2: HSC and iPSC Engineering and Therapy This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 5 Jose A. Vargas Asencio, Massachusetts Institute of Technology, USA Single Cell Sequencing of Developing Liver-Like Organoids Reveals Expression Programs Associated to Germ Line Trajectories Defined by Synthetic Circuits
Monday, February 10 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Monday, February 10 \| 5:00PM - 7:00PM Translational Science of Genome Editing: Assessing Specifici ty, Immunogenicity and Safety Room: Van Horne C Speaker 1 of 6 * Samantha Maragh, National institute of Standards and Technology, USA
Monday, February 10 \| 5:00PM - 7:00PM Translational Science of Genome Editing: Assessing Specifici ty, Immunogenicity and Safety Room: Van Horne C Speaker 2 of 6 Julian Grünewald, Massachusetts General Hospital, USA Advances in Identifying and Modulating the Specificities of Gene Editing Technologies
Monday, February 10 \| 5:00PM - 7:00PM Translational Science of Genome Editing: Assessing Specifici ty, Immunogenicity and Safety Room: Van Horne C Speaker 3 of 6 Richard A. Morgan, Editas Medicine, USA Application of Cpf1-Based Genome Editing for ex vivo Cell Therapy
Monday, February 10 \| 5:00PM - 7:00PM Translational Science of Genome Editing: Assessing Specifici ty, Immunogenicity and Safety Room: Van Horne C Speaker 4 of 6 Krishanu Saha, University of Wisconsin-Madison, USA Short Talk: Patient-Derived, Induced Pluripotent Stem Cells as Translational Tools to Assess Specificity, Immunogenicity, and Safety of Somatic Cell Genome Editors
Monday, February 10 \| 5:00PM - 7:00PM Translational Science of Genome Editing: Assessing Specifici ty, Immunogenicity and Safety Room: Van Horne C Speaker 5 of 6 Bruce R. Conklin, University of California, San Francisco, USA Short Talk: Modeling Therapeutic Editing in Patient-Derived iPSC Tissues
Monday, February 10 \| 5:00PM - 7:00PM Translational Science of Genome Editing: Assessing Specifici ty, Immunogenicity and Safety Room: Van Horne C Speaker 6 of 6 Zuben E. Sauna, Food and Drug Administration, USA Understanding and Navigating the Immune Responses to CRISPR-Associated Nuclease Cas9
Monday, February 10 \| 5:00PM - 7:00PM Cell Therapy for Infection and Autoimmune Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 5 * Marina Cavazzana, Paris Descartes University, France
Monday, February 10 \| 5:00PM - 7:00PM Cell Therapy for Infection and Autoimmune Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 5 Qizhi Tang, University of California, San Francisco, USA Manipulating Tregs to Control Tolerance in Autoimmunity and Organ Transplantation
Monday, February 10 \| 5:00PM - 7:00PM Cell Therapy for Infection and Autoimmune Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 5 Bruce R. Blazar, University of Minnesota, USA Treg Therapies in the Setting of Allogeneic HSCT
Monday, February 10 \| 5:00PM - 7:00PM Cell Therapy for Infection and Autoimmune Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 4 of 5 Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, USA Engineering Resistance to HIV Infection
Monday, February 10 \| 5:00PM - 7:00PM Cell Therapy for Infection and Autoimmune Diseases This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 5 Megan K. Levings, University of British Columbia, Canada CAR-Treg-Based Therapeutics
Monday, February 10 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Monday, February 10 \| 7:30PM - 10:00PM Poster Session 2 Room: Mezzanine 2
Tuesday, February 11 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 1 of 8 * Jennifer Gori, Obsidian Therapeutics, USA
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 2 of 8 Jacob E. Corn, ETH in Zurich, Switzerland How Human Cells Deal with Cas-Based Tools
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 3 of 8 Scot A. Wolfe, University of Massachusetts Medical School, USA Precise Therapeutic Gene Correction by a Simple Nuclease-Induced Double-Strand Break
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Coffee Break
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 5 of 8 Matthew Porteus, Stanford University School of Medicine, USA CRISPR Editing of Human HSCs
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 6 of 8 Shengdar Q. Tsai, St. Jude Children's Research Hospital, USA Short Talk: Highly Efficient Genome Editing of Human Hematopoietic Stem Cells and Fetal Hemoglobin Induction for Sickle Cell Disease Therapy
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 7 of 8 Alex Marson, University of California, San Francisco, USA Reprogramming Human Immune Cell Circuitry
Tuesday, February 11 \| 8:00AM - 11:00AM CRISPR-Based Editing of Non-Immune Cells (Joint) Room: Van Horne A/B Speaker 8 of 8 Connor A. Tsuchida, University of California, Berkeley; University of California, San Francisco, USA Short Talk: Engineering HIV-1 Virus-Like Particles for CRISPR-Cas9 Genome Engineering in Primary Human T Cells
Tuesday, February 11 \| 11:00AM - 5:00PM On Own for Lunch
Tuesday, February 11 \| 11:00AM - 1:00PM Poster Setup Room: Mezzanine 2
Tuesday, February 11 \| 1:00PM - 10:00PM Poster Viewing Room: Mezzanine 2
Tuesday, February 11 \| 2:30PM - 4:30PM Career Roundtable Room: Conservatory Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60. Speaker 1 of 6 Samuel Haile, Kite Pharma, USA
Tuesday, February 11 \| 2:30PM - 4:30PM Career Roundtable Room: Conservatory Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60. Speaker 2 of 6 Irene Jarchum, Nature, USA
Tuesday, February 11 \| 2:30PM - 4:30PM Career Roundtable Room: Conservatory Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60. Speaker 3 of 6 Zuben E. Sauna, Food and Drug Administration, USA
Tuesday, February 11 \| 2:30PM - 4:30PM Career Roundtable Room: Conservatory Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60. Speaker 4 of 6 Yvonne Y. Chen, University of California, Los Angeles, USA
Tuesday, February 11 \| 2:30PM - 4:30PM Career Roundtable Room: Conservatory Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60. Speaker 5 of 6 Kole T. Roybal, University of California, San Francisco, USA
Tuesday, February 11 \| 2:30PM - 4:30PM Career Roundtable Room: Conservatory Interested participants must sign up at the registration desk on a first-come, first-serve basis. Maximum attendance: 60. Speaker 6 of 6 Eric J. Perkins, Addgene, USA
Tuesday, February 11 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Tuesday, February 11 \| 5:00PM - 7:00PM “Off the Shelf” Allogeneic Cell Therapies (Joint) Room: Van Horne A/B Speaker 1 of 6 * Crystal L. Mackall, Stanford University, USA
Tuesday, February 11 \| 5:00PM - 7:00PM “Off the Shelf” Allogeneic Cell Therapies (Joint) Room: Van Horne A/B Speaker 2 of 6 * Richard A. Morgan, Editas Medicine, USA
Tuesday, February 11 \| 5:00PM - 7:00PM “Off the Shelf” Allogeneic Cell Therapies (Joint) Room: Van Horne A/B Speaker 3 of 6 Daniel Shoemaker, Fate Therapeutics, USA Next Generation iPSC Derived Cellular Immunotherapies for Cancer
Tuesday, February 11 \| 5:00PM - 7:00PM “Off the Shelf” Allogeneic Cell Therapies (Joint) Room: Van Horne A/B Speaker 4 of 6 Hanspeter Waldner, CRISPR Therapeutics, USA Development of an Allogeneic T Cell Therapy for Oncology
Tuesday, February 11 \| 5:00PM - 7:00PM “Off the Shelf” Allogeneic Cell Therapies (Joint) Room: Van Horne A/B Speaker 5 of 6 Sonja Schrepfer, University of California, San Francisco, USA Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immunocompetent Allogeneic Recipients
Tuesday, February 11 \| 5:00PM - 7:00PM “Off the Shelf” Allogeneic Cell Therapies (Joint) Room: Van Horne A/B Speaker 6 of 6 Theodore Roth, University of California, San Francisco, USA Short Talk: Highly Parallel Knock-In Targeting for Genome Engineering of Cellular Immunotherapies
Tuesday, February 11 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Mezzanine 2 No registration fees are used to fund alcohol served at this function.
Tuesday, February 11 \| 7:30PM - 10:00PM Poster Session 3 Room: Mezzanine 2
Wednesday, February 12 \| 7:00AM - 8:00AM Breakfast Room: Mezzanine 2
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 1 of 8 * Cecilia Cotta-Ramusino, Tessera Therapeutic, USA
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 2 of 8 James E. Haber, Brandeis University, USA Understanding Cas9-Mediated Gene Targeting by Single-Strand Template Repair
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 3 of 8 Pavel Zrazhevskiy, Altius Institute for Biomedical Sciences, USA Short Talk: Single Molecule Imaging of Nuclease-Induced Double Strand Break Repair in Human Cells
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 4 of 8 Gaelle Legube, Center for Integrative Biology, France Transcription Coupled DNA Double Strand Break Repair: Dealing with Breaks on Transcribed Loci
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Coffee Break
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 6 of 8 Jonathan K. Watts, University of Massachusetts Medical School, USA Chemically Modified DNA Donors for Precision Genome Editing
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 7 of 8 Albert B. Seymour, Homology Medicines, USA AAVHSC-Mediated Genome Editing through Homologous Recombination: Applications in Liver-Mediated Diseases
Wednesday, February 12 \| 8:00AM - 11:00AM DNA Repair and Genome Editing Room: Van Horne C Speaker 8 of 8 Manda Arbab, Harvard University and Broad Institute, USA Short Talk: Predictable and Precise Genome Editing Enabled by Systematic Characterization of Editing Outcomes
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 10 * Alex Marson, University of California, San Francisco, USA
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 10 Christine E. Brown, Beckman Research Institute, City of Hope, USA Advancing CAR T Cell Therapy for Treatment of Brain Tumors
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 10 Kole T. Roybal, University of California, San Francisco, USA Engineering Next-Generation Immune Cell Therapies for Solid Tumors
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Coffee Break
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 10 Marius Wernig, Stanford University, USA How to Make a Neuron
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 6 of 10 H. Kay Chung, The Salk Institute for Biological Studies, USA Short Talk: A Compact Synthetic Pathway Rewires Cancer Signaling to Therapeutic Effector Release
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 7 of 10 Andrew Ng, University of California, San Francisco, USA Short Talk: Modular and Tunable Biological Feedback Control Using a De Novo Protein Switch
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 8 of 10 Nika Shakiba, Massachusetts Institute of Technology, USA Short Talk: Synthetic Genetic Feedback Control Circuits to Reprogram Cell Fate
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 9 of 10 Noreen Wauford, Massachusetts Institute of Technology, USA Short Talk: Development of a Toggle Switch Based on Post-Transcriptional Regulation that Resists Epigenetic Silencing
Wednesday, February 12 \| 8:00AM - 11:15AM Using Synthetic Biology to Enhance Safety and Efficacy of Ce llular Therapeutics This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 10 of 10 Louai Labanieh, Stanford University, USA Short Talk: Genetically-Encoded Switches for Improving CAR-T Immunotherapy
Wednesday, February 12 \| 11:00AM - 5:00PM On Own for Lunch
Wednesday, February 12 \| 4:30PM - 5:00PM Coffee Available Room: Van Horne Foyer
Wednesday, February 12 \| 5:00PM - 6:45PM New Genome Editing Tools Room: Van Horne C Speaker 1 of 5 * Scot A. Wolfe, University of Massachusetts Medical School, USA
Wednesday, February 12 \| 5:00PM - 6:45PM New Genome Editing Tools Room: Van Horne C Speaker 2 of 5 Erik Sontheimer, University of Massachusetts Medical School, USA Editing Genomes with Engineered Guide RNAs and Compact, Accurate Cas9 Homologs
Wednesday, February 12 \| 5:00PM - 6:45PM New Genome Editing Tools Room: Van Horne C Speaker 3 of 5 Yan Zhang, University of Michigan, USA Long-Range Genome Engineering in Human Cells with CRISPR-Cas3
Wednesday, February 12 \| 5:00PM - 6:45PM New Genome Editing Tools Room: Van Horne C Speaker 4 of 5 David R. Liu, Broad Institute, HHMI, and Harvard University, USA Base Editing and Prime Editing: Genome Editing Without Double-Strand Breaks
Wednesday, February 12 \| 5:00PM - 6:45PM New Genome Editing Tools Room: Van Horne C Speaker 5 of 5 Peter J. Chen, Harvard University, USA Short Talk: Programmable m6A Modification of RNA with a Cas13-Directed Methyltransferase
Wednesday, February 12 \| 5:00PM - 6:45PM Non-T Immune Cell Therapies This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 1 of 5 * Crystal L. Mackall, Stanford University, USA
Wednesday, February 12 \| 5:00PM - 6:45PM Non-T Immune Cell Therapies This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 2 of 5 Katy Rezvani, University of Texas MD Anderson Cancer Center, USA Off-The-Shelf CAR-Engineered Cord Blood-Derived NK Cells for the Treatment of Cancer
Wednesday, February 12 \| 5:00PM - 6:45PM Non-T Immune Cell Therapies This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 3 of 5 Jeffrey S. Miller, University of Minnesota, USA Novel Strategies to Activate and Target NK Cells as Off-The-Shelf Therapy to Treat Cancer
Wednesday, February 12 \| 5:00PM - 6:45PM Non-T Immune Cell Therapies This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 4 of 5 Leonid S. Metelitsa, Baylor College of Medicine, USA NKT Cells as a Platform for Adoptive Cancer Immunotherapy
Wednesday, February 12 \| 5:00PM - 6:45PM Non-T Immune Cell Therapies This session is from Emerging Cellular Therapies Room: Van Horne A/B Speaker 5 of 5 Eric Lagasse, University of Pittsburgh, USA Short Talk: The Lymph Node as an Ectopic Transplantation Site for Hepatocytes
Wednesday, February 12 \| 6:45PM - 7:00PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) Room: Van Horne C
Wednesday, February 12 \| 6:45PM - 7:00PM Meeting Wrap-Up: Outcomes and Future Directions (Organizers) This session is from Emerging Cellular Therapies Room: Van Horne A/B
Wednesday, February 12 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Alberta/New Brunswick No registration fees are used to fund alcohol served at this function.
Wednesday, February 12 \| 8:00PM - 11:00PM Entertainment Room: Alberta/New Brunswick Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Thursday, February 13 \| 10:24AM - 10:24AM Departure *Session Chair †Invited, not yet responded.